The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure

No abstract is available for this paper.

• Publication year

  2003

• Venue

  International Journal of Geriatric Psychiatry

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/GPS.826PMID 12673604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 5-month, randomized, placebo-controlled trial of galantamine in AD

  2000cited by this paper
• Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension

  2000cited by this paper
• Galantamine in AD

  2000cited by this paper
• The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease.

  1999cited by this paper
• The cholinergic hypothesis of Alzheimer’s disease: a review of progress

  1999cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw

  1999cited by this paper
• Behavioural status during the intracarotid amobarbital procedure (Wada test): relevance for surgical management

  1999influential reference
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  1999cited by this paper
• Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

  1998cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study

  1996cited by this paper
• The role of nicotinic receptors in the pathophysiology of Alzheimer's disease.

  1989cited by this paper

• Determination of the Chemical Composition, Antioxidant, and Enzyme Inhibitory Activity of Onosma mollis DC

  2021cites this paper
• Dual Prophylactic/Therapeutic Potential of Date Seed, and Nigella and Olive Oils-based Nutraceutical Formulation in Rats with Experimentally-Induced Alzheimer's Disease: A Mechanistic Insight.

  2020cites this paper
• Enhancing Therapeutic Efficacy of Donepezil by Combined Therapy; A Comprehensive Review.

  2020cites this paper
• History and progress of hypotheses and clinical trials for Alzheimer’s disease

  2019cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined

  2017cites this paper
• Predicting the neural effect of switching from donepezil to galantamine based on single‐photon emission computed tomography findings in patients with Alzheimer's disease

  2016cites this paper
• Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil

  2016cites this paper
• Cholinesterase inhibitory, anti-amyloidogenic and neuroprotective effect of the medicinal plant Grewia tiliaefolia – An in vitro and in silico study

  2016cites this paper
• Treatment of Alzheimer’s Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions

  2015cites this paper
• Title Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN 2 B-NMDAR responses

  2014cites this paper
• Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN2B-NMDAR responses

  2014cites this paper
• A life span approach to the relationship between cholesterol, late onset Alzheimer's disease, and cognitive functioning among older adults

  2014cites this paper
• Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil

  2013cites this paper
• Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates.

  2013cites this paper
• Chronic treatment with rivastigmine in patients with Alzheimer's disease: a study on primary motor cortex excitability tested by 5 Hz-repetitive transcranial magnetic stimulation.

  2012cites this paper
• Alzheimer's disease and age-related memory decline (preclinical).

  2011influential citation
• SELECT CAUSES , DIAGNOSIS , AND TREATMENT 2 An Examination into Select Causes , Diagnosis , and Treatment of Alzheimer ’ s Disease

  2010cites this paper
• [Pathogenetic and therapeutic aspects of dementia in Parkinson's disease].

  2009cites this paper
• meta-analytic review dementia and Alzheimer's disease: a Neuropsychological deficits in frontotemporal

  2008cites this paper
• Neuropsychological deficits in frontotemporal dementia and Alzheimer’s disease: a meta-analytic review

  2007cites this paper
• Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease.

  2007cites this paper
• Combination of Rimonabant and Donepezil Prolongs Spatial Memory Duration

  2007cites this paper
• Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats.

  2007cites this paper
• Galantamine for Alzheimer's disease and mild cognitive impairment.

  2006cites this paper
• Comparison of Galantamine and Donepezil for Effects on Nerve Growth Factor, Cholinergic Markers, and Memory Performance in Aged Rats

  2006cites this paper
• Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment

  2005cites this paper
• Galantamine: use in Alzheimer’s disease and related disorders

  2004cites this paper
• Galantamine for Alzheimer's disease.

  2004cites this paper
• Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.

  2004cites this paper
• Galantamine for Alzheimer's disease.

  2004cites this paper
• Current awareness in human psychopharmacology.

  2003cites this paper
• The Cholinesterase Inhibitors

  2003cites this paper
• Current awareness in human psychopharmacology

  2003cites this paper
• Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents

  2003cites this paper